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Abstract
Background: Prostate cancer is a significant health problem among American men. Treatment
strategies for androgen-independent cancer are currently not available. Tumor necrosis factor-
related apoptosis-inducing ligand (Apo2L/TRAIL) is a death receptor ligand that can induce
apoptosis in a variety of cancer cell lines, including androgen-independent PC3 prostate carcinoma
cells.  In vitro, TRAIL-mediated apoptosis of prostate cancer cell lines can be enhanced by
doxorubicin and correlates with the downregulation of the anti-apoptotic protein c-FLIP. This
study evaluated the effects of doxorubicin on c-FLIP expression and tumor growth in combination
with Apo2L/TRAIL in a xenograft model.
Methods: In vitro cytotoxic effects of TRAIL were measured using a MTS-based viability assay. For
in vivo studies, PC3 prostate carcinoma cells were grown subcutaneously in athymic nude mice and
tumor growth was measured following treatment with doxorubicin and/or Apo2L/TRAIL. c-FLIP
expression was determined by western blot analysis. Apoptosis in xenografts was detected using
TUNEL. Statistical analysis was performed using the student t-test.
Results: In vitro experiments show that PC3 cells are partially susceptible to Apo2L/TRAIL and that
susceptibility is enhanced by doxorubicin. In mice, doxorubicin did not significantly affect the
growth of PC3 xenografts but reduced c-FLIP expression in tumors. Expression of c-FLIP in mouse
heart was decreased only at the high doxorubicin concentration (8 mg/kg). Combination of
doxorubicin with Apo2L/TRAIL resulted in more apoptotic cell death and tumor growth inhibition
than Apo2L/TRAIL alone.
Conclusions:  Combination of doxorubicin and Apo2L/TRAIL is more effective in growth
inhibition of PC3 xenografts in vivo than either agent alone and could present a novel treatment
strategy against hormone-refractory prostate cancer. The intracellular mechanism by which
doxorubicin enhances the effect of Apo2L/TRAIL on PC3 xenografts may be by reducing
expression of c-FLIP.
Background
Prostate cancer is a significant health problem among
American men. This year about 230,110 men will be diag-
nosed with the disease and about 30,000 will likely die in
this country alone [1]. Treatment options are limited and
are associated with significant morbidity and mortality
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[2]. Localized cancer is treated with radical prostatectomy,
brachy- or cryotherapy, and external beam radiation while
cancer that has escaped the prostatic capsule is generally
treated by androgen ablation. However, the eventual
development of an androgen-independent phenotype
leads to incurable disease, indicating the need for better
treatment strategies. Experimental approaches include
delivery of oncolytic viruses, immunomodulatory mole-
cules, p53 and p21, enzymes that metabolize prodrugs
and agents that can induce apoptosis [3]. One agent that
has received considerable attention as a novel apoptosis-
inducing agent is tumor necrosis factor-related apoptosis
inducing ligand (TRAIL/Apo2L).
TRAIL is a type II membrane protein that can induce
apoptosis by binding to death domain containing recep-
tors DR4 and DR5 [4]. Unlike other death receptor ligands
such as TNF and FasL, which cause septic shock and hepa-
totoxicity, respectively, TRAIL is tolerated well in mice and
non-human primates [5-7]. TRAIL induces apoptosis in a
variety of cell lines in vitro and in vivo. Apoptosis is initi-
ated by binding to receptors DR4/DR5 (TRAIL-R1, 2),
which is followed by assembly of the death inducing sig-
naling complex and activation of caspase-8. Subsequent
activation of caspases-3/7 (in a mitochondria-dependent
or independent fashion) leads to execution of apoptosis
[4].
Active caspase-8 tetramers are generated by cis- and tran-
scatalytic cleavage from pro-caspase-8 homodimers [8].
These cleavage steps are inhibited by heterodimer forma-
tion of caspase-8 with c-FLIP. The apoptosis inhibitor c-
FLIP is structurally similar to caspase-8 but lacks the
cysteine residue essential for catalytic activity. A strong
correlation between c-FLIP expression and malignant
potential has been observed in carcinomas of the colon
and liver as well as melanomas [9-11]. In addition, a high
c-FLIP/caspase-8 ratio has been associated with resistance
to death receptor-mediated apoptosis [11-13]. Thus
downregulation of c-FLIP is a desirable strategy to
enhance the apoptotic response to death receptor ligands.
We have previously shown that prostate cancer cells are
relatively resistant to recombinant TRAIL but can be sen-
sitized by pretreatment with the chemotherapeutic agent
doxorubicin [7,14]. The enhanced susceptibility of pros-
tate cancer cells was independent of androgen-phenotype
or p53 status but correlated with doxorubicin-mediated
downregulation of c-FLIP expression. In this study we
extended those observations to an in vivo model using
xenografts of PC3 prostate carcinoma cells.
Our results show that doxorubicin reduces c-FLIP expres-
sion in xenografts and that combination of doxorubicin
with TRAIL is more effective in tumor growth inhibition
than either agent alone.
Methods
Cells and reagents
PC3 cells were purchased from the ATCC and were main-
tained in RPMI1640 supplemented with 10% FBS at 37°C
with 5% CO2. Apo2L/TRAIL was generously provided by
Genentech Inc., San Francisco CA. KillerTRAIL was pur-
chased from Alexis, San Diego, CA. Doxorubicin was
obtained from the MUSC pharmacy. The CellTiter Aque-
ous One Solution Cell Proliferation Assay and DeadEnd-
TUNEL kits were purchased from Promega, Madison WI.
The c-FLIP antibody NF-6 was kindly provided by Dr.
Marcus Peter, University of Chicago. The Dave-2 (c-FLIP)
antibody and anti-actin were purchased from Alexis, San
Diego, CA and from Sigma, St. Louis, MO, respectively.
Supersignal DuraWest was obtained from Pierce Biotech-
nology Inc., Rockford, IL.
MTS viability assay
Cells were seeded into 96-well plates at 1 × 104 cells/well,
incubated overnight and subsequently treated with doxo-
rubicin and/or Killer-TRAIL/Apo2L/TRAIL. The MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] reagent was added 24
hours after initiation of treatment and plates read at an
absorbance of 490 nm one to two hours later using a
Vmax kinetic microplate reader (Molecular Devices, Sun-
nyvale, CA). All treatments were performed in triplicate.
Background absorbance was determined by incubating
media with substrate alone and subtracting the values
from wells containing cells. Percent cytotoxicity was calcu-
lated as follows: % cytotoxicity = 1 - [(OD of experimen-
tal/OD of control) × 100]. Experiments were repeated
three times with similar results. There were no discrepan-
cies between results obtained in the MTS assay and visual
assessment of the cells prior to adding the MTS reagent.
Animal experiments
Athymic male nude mice (3–4 weeks old) were purchased
from Harlan, Indianapolis IN and were housed under
pathogen-free conditions according to Medical University
of South Carolina animal care guidelines. All animal
experiments were reviewed and approved by the Institu-
tional Animal Care and Use Committee at MUSC. PC3
cells (4 × 106) were injected subcutaneously into the
flanks of mice. Animals bearing tumors were randomly
assigned to treatment groups (five or six mice per group)
and treatment initated when xenografts reached volumes
of about 100 mm3. Tumors were measured using digital
calipers and volume calculated using the formula: Volume
= Width2 × Length × 0.52, where width represents the
shorter dimension of the tumor. Treatments were admin-
istered as indicated using vehicle (PBS containing 0.1%BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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BSA), doxorubicin (2–8 mg/kg), Apo2L/TRAIL (500 µg/
animal), or a combination of 4 mg/kg doxorubicin fol-
lowed by 500 µg Apo2L/TRAIL. Doxorubicin was admin-
istered systemically whereas Apo2L/TRAIL was given
either intra-tumorally (Fig 4) or systemically (Fig 5). All
treatments were given once. Mice were monitored daily
for signs of adverse effects (listlessness and scruffy appa-
rance). Treatments seemed to be well tolerated. The mean
± SEM was calculated for each data point. Differences
between treatment groups were analyzed by the student t-
test. Differences were considered significant when P <
0.05.
Western blotting
Following doxorubicin treatment, mice were sacrificed,
tissue removed and immediately frozen in liquid nitro-
gen. Protein was prepared in RIPA buffer containing
freshly added mammalian protease inhibitor cocktail.
Lysates were stored at -70°C and were centrifuged (20,000
× g) prior to performing protein assays on the
Cytotoxic effects of KillerTRAIL and Apo2L/TRAIL in vitro Figure 1
Cytotoxic effects of KillerTRAIL and Apo2L/TRAIL in vitro. PC3 cells were incubated with ligand at the indicated con-
centrations without (A), or with 0.25 µg/ml (B), 0.5 µg/ml (C) or 1 µg/ml (D) doxorubicin for 24 hours. Data shown are the 
mean ± SEM from a representative experiment. Similar results have been obtained three times.BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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supernatant. Protein (50 µg) was separated on 4–12% Bis/
Tris NuPage gels in MES buffer and transferred to nitrocel-
lulose for 60–90 minutes at 30 V. After transfer and block-
ing (5% milk), blots were probed with Dave-2 (1:500 in
0.5 % milk) or NF-6 (1:5 in TBS-Tween) overnight at
room temperature. Following three washes with TBS-
Tween, membranes were incubated with the anti-mouse
(1:5,000) or anti-rat (1:15,000) HRP-conjugated second-
ary antibodies for 1 hour at room temperature in 5% milk
in TBS-Tween. Membranes were washed three times in
TBS-Tween followed by chemiluminescent detection of
the secondary conjugates with DuraWest Supersignal.
Membranes were reprobed with anti-actin (1:2000) to
ensure equal loading.
TUNEL staining
Tumors were excised and fixed in 10% formalin and proc-
essed by standard procedures. Sections were analysed for
apoptotic cells using the DeadEND Tunel kit according to
the manufacturers instructions. Stained slides were exam-
ined for TUNEL positive cells using a Zeiss Axiovert 200
microscope (20×). TUNEL positive cells from 4 fields/
slide were counted by two investigators to calculate the
mean ± SEM. P-values were calculated using the student's
t-test.
Results
Comparison of KillerTRAIL and Apo2L/TRAIL in vitro
We have previously shown that the TRAIL apoptotic
response in prostate cancer cells can be enhanced by dox-
orubicin [14,15]. These studies were conducted using Kill-
erTRAIL, a commercially available form of the protein that
is crosslinked for maximal activity and contains a histi-
dine tag. Concerns about hepatotoxicity were raised when
a polyhistidine tagged recombinant version of TRAIL
induced apoptosis in human hepatocytes [16]. A subse-
quent study revealed that different recombinant versions
of TRAIL vary widely in their biochemical properties and
their potential to cause toxicity. TRAIL containing a histi-
dine tag (Apo2L/TRAIL.His) contained less Zinc, had a
less ordered conformation and was more heterogeneous
than TRAIL without a tag (Apo2L/TRAIL.0) [17]. In con-
trast to Apo2L/TRAIL.His, Apo2L/TRAIL.0 was non-toxic
to human hepatocytes. Thus non-tagged Apo2L/TRAIL.0
(referred to as Apo2L/TRAIL) is the preferable form to use
in preclinical studies.
Initially we compared the susceptibility of PC3 prostate
carcinoma cells to KillerTRAIL and Apo2L/TRAIL in paral-
lel assays in vitro. As shown in Figure 1A, at 1000 ng/ml
KillerTRAIL resulted in about 50% cytotoxicity whereas
less than 20% cytotoxicity was obtained with Apo2L/
TRAIL. This difference may stem from the histidine tag of
KillerTRAIL. In the presence of doxorubicin, KillerTRAIL
and Apo2L/TRAIL were about equally effective (Fig 1B–
D). Doxorubicin lowered the concentration requirement
for TRAIL with near maximal killing achieved at 10 ng/ml
ligand.
Effect of doxorubicin on growth and c-FLIP expression in 
vivo
To determine an appropriate dose of doxorubicin for the
in vivo experiments, mice bearing PC3 xenografts were
injected with 2, 4 or 8 mg/kg doxorubicin and tumor vol-
ume was measured over time (Figure 2). A dose of 2 mg/
kg did not affect tumor growth while higher dosages
delayed tumor growth initially (p < 0.05 at days 18 and
22). However, no statictically significant differences were
detected between untreated and doxorubicin treated
groups at later time points.
Previously, we have examined possible targets of doxoru-
bicin that may be responsible for increasing the suscepti-
bility of prostate cancer cells to TRAIL in vitro. These
included TRAIL receptors, Bax, Bcl-2, Bcl-xl, and c-FLIP
[15]. In PC3 cells, the only change observed in response
to doxorubicin was a decrease in c-FLIP that correlated
with onset and magnitude of caspase-8 activation and
apoptosis. To investigate whether doxorubicin would
have a similar effect on c-FLIP in vivo, protein from PC3
xenografts was isolated for western blotting 24 hours after
systemic delivery of the drug. As shown in Figure 3A, we
found that either 4 mg/kg or 8 mg/kg doxorubicin signif-
icantly reduced levels of c-FLIP in PC3 xenografts. The
antibody used for the detection of c-FLIP (NF-6) is
human-specific and thus detects only c-FLIP of PC3 ori-
gin. We also investigated the effect of doxorubicin on c-
FLIP in the heart from the same mice. The heart was cho-
sen because it expresses high levels of c-FLIP [18]. In addi-
tion, c-FLIP-deficient mice do not survive past day 10.5 of
embryogenesis due to impaired heart development [19],
indicating that c-FLIP plays a critical role in this organ.
Protein isolated from the heart was analyzed with the rat
monoclonal antibody Dave-2 that detects both mouse
and human c-FLIP, although all c-FLIP detected should be
exclusively of mouse origin, since PC3 cells are grown sub-
cutaneously. Two major proteins, each migrating some-
what slower than the human c-FLIP isoforms, were
detected with the Dave-2 antibody (Fig. 3B). The signal of
the lower band (c-FLIPS) was not diminished following
doxorubicin treatment, whereas the signal of the upper
band (c-FLIPL) was slightly reduced following administra-
tion of 8 mg/kg doxorubicin. Since 4 mg/kg doxorubicin
reduced c-FLIP in PC3 xenografts as effectively as 8 mg/kg
without affecting endogenous mouse c-FLIP, this dose was
chosen for combination therapy.BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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Effectiveness of Apo2L/TRAIL doxorubicin combination 
therapy in vivo
To determine apoptosis in vivo following treatments, mice
bearing bilateral PC3 xenografts were injected
systemically with vehicle or 4 mg/kg doxorubicin, fol-
lowed by intratumoral injection of vehicle (left tumor) or
Apo2L/TRAIL (right tumor). Twenty-four hours after
Apo2L/TRAIL injection, tumors were harvested and ana-
lysed for apoptosis by TUNEL staining (Fig. 4). There was
no significant difference in TUNEL-positive cells in con-
trol and doxorubicin treated tumors. Treatment with
Apo2L/TRAIL resulted in 70% more apoptotic cells than
in vehicle treated tumors. However, combination treat-
ment of doxorubicin and Apo2L/TRAIL yielded the most
TUNEL positive cells (278% compared to the control) and
was statistically different from all other treatment groups.
Next, we determined whether this pattern would be
reflected in tumor growth of PC3 xenografts. Animals
received systemic admininstration of doxorubicin fol-
lowed by systemic injection of TRAIL after 24 hours, when
c-FLIP levels were expected to have decreased. Tumors in
animals injected with doxorubicin reached volumes of
approximately 1000 mm3 within 26 days after treatment
The effect of doxorubicin on growth of PC3 xenografts Figure 2
The effect of doxorubicin on growth of PC3 xenografts. Athymic nude mice were injected with PC3 cells (day 0) and 
treated with doxorubicin (i.p.) on day 10. Tumor size in animals treated with 4 or 8 mg/kg doxorubicin were significantly differ-
ent from the untreated group on day 18 and 22, P < 0.05.BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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initiation (1025 ± 138 mm3), which was not significantly
different from the control group (1025 ± 118 mm3, p =
0.41). Tumors in animals treated with Apo2L/TRAIL were
reduced compared to either untreated or doxorubicin
treated groups (833.5 ± 150 mm3, p = 0.03). However,
tumors that had been exposed to both doxorubicin and
Apo2L/TRAIL were significantly smaller (224 ± 145 mm3,
p < 0.001) and remained smaller at day 33 (490 ± 197
mm3) when the experiment was terminated. Analysis of
tumor volume over time suggests that a single round of
combination treatment delays growth until day 26 (Fig
5C). After tumors escape this delay they resume growth at
rates similar to the other groups.
Discussion
In this study we have shown that combination of Apo2L/
TRAIL and doxorubicin is more effective in retarding
tumor growth of PC3 prostate carcinoma xenografts than
either agent alone. Doxorubicin is an anthracycline,
which intercalates into DNA thereby activating DNA
repair pathways and elevating levels of p53. PC3 cells are
p53-/-, which may explain why doxorubicin as a single
agent was relatively uneffective against tumor growth
inhibition [20]. However doxorubicin was able to reduce
expression of the anti-apoptotic protein c-FLIP in vivo. We
have previously shown that sequential treatment of doxo-
rubicin followed by TRAIL resulted in cell death in vitro
[15]. Our data suggest that downregulation of c-FLIP is an
important step in vivo that enhances TRAIL-induced apop-
tosis as evidenced by increased TUNEL staining in tumors
treated with combination therapy. Other agents that
reduce c-FLIP and increase death ligand mediated apopto-
sis include cycloheximide, 9-nitrocamptothecin, cisplatin,
and the proteasome inhibitor PS-341 [21-24]. These
agents affect multiple cellular responses suggesting that
downregulation of c-FLIP may not be the sole factor by
which death ligand-induced apoptosis is enhanced. How-
ever, selective reduction of c-FLIP using RNA interference
or anti-sense technology is sufficient to sensitize human
cell lines, including Du145 prostate carcinoma cells to
death receptor ligands, indicating that c-FLIP is a major
provider of resistance in this apoptotic pathway [25,26].
Tumors in mice that received Apo2L/TRAIL alone were
about 20% smaller than those of the control group. Thus
the growth inhibitory effect of Apo2L/TRAIL on PC3
Effect of doxorubicin on c-FLIP in vivo Figure 3
Effect of doxorubicin on c-FLIP in vivo Mice bearing PC3 xenografts were untreated or treated with 4 mg/kg or 8 mg/kg 
doxorubicin (i.p.). After 24 hours, protein was isolated from xenografts (A) or mouse heart (B) and probed for c-FLIP expres-
sion by western blotting. Actin was included as a loading control.BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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xenografts in vivo was reflective of the results obtained in
vitro. In contrast to single agent therapy, combination
treatment with doxorubicin and TRAIL resulted in tumors
that had 80% less volume than those in the control group.
Tumors that received combination therapy continued to
grow slowly, indicating that complete regression of PC3
xenografts was not achieved using a single treatment. In a
recent study, PC3 xenografts were treated with irradiation
followed by TRAIL, which resulted in complete growth
inhibiton following three weekly rounds of therapy [27].
This indicates that multiple treatments may be neccessary
to achieve a complete response.
We observed that a single administration of 4 mg/kg dox-
orubicin reduced cFLIP protein in PC3 xenografts but not
mouse heart. One possibility is that cFLIP expression is
differentially affected in normal versus malignant cells. If
so, then doxorubicin would preferentially lower the apop-
totic threshold in cancer cells and facilitate the selective
elimination of these cells. Alternatively, the difference
may be species specific. When grown in mice, human
xenografts of various origins have successfully been
treated by TRAIL in combination with other agents
[5,24,27-29]. In contrast, combination of doxorubicin
and TRAIL in vitro can induce cell death in normal human
breast, mesothelial, or prostate epithelial cells, [14,30,31],
which suggests that combination therapy may lack specif-
icity when applied to humans. Could combination ther-
apy in mice be non-toxic because endogenous mouse c-
FLIP remains unaffected by chemotherapy? To avoid the
TUNEL staining of PC3 xenografts Figure 4
TUNEL staining of PC3 xenografts Mice bearing bilateral PC3 xenografts were untreated or treated with doxorubicin 
(i.p.) before receiving intratumoral injections of 500 µg Apo2L/TRAIL (left) or vehicle (right). After 24 hours, tumors were har-
vested, fixed, processed and analysed for TUNEL staining. Data shown are the mean ± SEM calculated from TUNEL positive 
cells counted in four fields.BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
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possible complication of toxicity the effect of chemother-
apy on c-FLIP expression in human patients should be
carefully evaluated before considering systemic combina-
tion of chemotherapy and Apo2L/TRAIL.
Conclusions
We found that combination of doxorubicin chemother-
apy and Apo2L/TRAIL is more effective in tumor growth
inhibition than either agent alone, indicating that this
may represent a novel treatment strategy against prostate
cancer. One of the mechanisms by which doxorubicin
may enhance Apo2L/TRAIL apoptosis in PC3 xenografts is
reduced expression of the anti-apoptotic protein c-FLIP.
Future studies are needed to further investigate the effect
of chemotherapy on c-FLIP in human patients and to
optimize the treatment schedule to achieve complete
tumor regression.
Competing interests
The author(s) declare that they have no competing
interests
Authors' contribution
AZ carried out the animal experiments using doxorubicin
and Apo2L/TRAIL and TUNEL staining. JM carried out the
animal experiments using doxorubicin. CVJ carried out
viability assays and western blot analysis, conceived of the
study, participated in its design and coordination, and
prepared the manuscript. All authors read and approved
the final manuscript.
Acknowledgements
The authors would like to thank Genentech for its generous supply of 
Apo2L/TRAIL, Dr. Marcus Peter for the NF-6 hybridoma supernan and 
Margaret Romano from the Hollings Cancer Center histopathology core 
laboratory for excellent technical assistance. This research was supported 
by grants from the Department of Defense (N6311600MDM0601) and 
National Institutes of Health (NIH RO1 CA102218) to CVJ.
References
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer
EJ, Thun MJ: Cancer Statistics 2004. CA Cancer J Clin 2004, 54:8-29.
2. Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK:
SEER Cancer Statistics Review, 1973-1994. National Cancer
Institute. NIH Pub No 97-2789 1997.
3. Steiner MS, Gingrich JR: Gene Therapy for Prostate Cancer:
Where are we now? Journal of Urology 2000, 164:1121-1136.
Effect of combination therapy on the growth of PC3 xenografts Figure 5
Effect of combination therapy on the growth of PC3 xenografts Mice bearing PC3 xenografts were untreated or 
treated with 4 mg/kg doxorubicin (i.p.), followed by either vehicle or 500 µg Apo2L/TRAIL (i.p.). Data shown represent tumor 
size twenty-six days after treatment was initiated (A). Tumor size in animals treated with combination therapy was monitored 
an additional week (33 days after treatment initiation) (B). Tumor growth over time (C) demonstrates that tumor growth is 
significantly different on and after day 21 (* indicates p < 0.05).Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:2 http://www.biomedcentral.com/1471-2407/5/2
Page 9 of 9
(page number not for citation purposes)
4. MacFarlane M: TRAIL-induced signalling and apoptosis. Toxicol-
ogy Letters 2003, 139:89-97.
5. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA,
Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis
IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH:
Safety and antitumor activity of recombinant soluble Apo2
ligand. Journal of Clinical Investigation 1999, 104:155-162.
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin
W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG,
Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor
necrosis factor-related apoptosis-inducing ligand in vivo [see
comments]. Nature Medicine 1999, 5:157-163.
7. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA:
Preclinical studies to predict the disposition of Apo2L/tumor
necrosis factor-related apoptosis-inducing ligand in humans:
Characterization of in vivo efficacy, pharmacokinetics, and
safety. J Pharmacol Exp Ther 2001, 299:31-38.
8. Krueger A, Baumann S, Krammer PH, Kirchhoff S: FLICE-Inhibi-
tory Proteins: Regulators of Death Receptor-Mediated
Apoptosis. Mol Cell Biol 2001, 21:8247-8254.
9. Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH,
Tschopp J, French LE: Selective expression of FLIP in malignant
melanocytic skin lesions. Journal of Investigative Dermatology 2001,
117:360-364.
10. Ryu BK, Lee MG, Chi SG, Kim YW, Park JH: Increased expression
of cFLIP(L) in colonic adenocarcinoma.  Journal of Pathology
2001, 194:15-19.
11. Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M,
Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K, Nakano T:
Cellular FLICE/caspase-8-inhibitory protein as a principal
regulator of cell death and survival in human hepatocellular
carcinoma. Laboratory Investigation 2003, 83:1033-1043.
12. Tepper CG, Seldin MF: Modulation of caspase-8 and FLICE-
inhibitory protein expression as a potential mechanism of
Epstein-Barr virus tumorigenesis in Burkitt's lymphoma.
blood 1999, 94:1727-1737.
13. Jonsson G, Paulie S, Grandien A: High level of cFLIP correlates
with resistance to death receptor-induced apoptosis in blad-
der carcinoma cells. Anticancer Research 2003, 23:1213-1218.
14. Voelkel-Johnson C, King DL, Norris JS: Resistance of prostate
cancer cells to soluble TNF-related apoptosis-inducing lig-
and (TRAIL/Apo2L) can be overcome by doxorubicin or ade-
noviral delivery of full-length TRAIL. Cancer Gene Therapy 2002,
9:164-172.
15. Kelly MM HBHVJC: Doxorubicin pretreatment sensitizes pros-
tate cancer cell lines to TRAIL induced apoptosis which cor-
relates with the loss of c-FLIP expression. Cancer Biology &
Therapy 2002, 1:520-527.
16. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC:
Apoptosis induced in normal human hepatocytes by tumor
necrosis factor-related apoptosis-inducing ligand [see
comments]. Nature Medicine 2000, 6:564-567.
17. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B,
Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R,
Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S,
Fox JA, Thomas D, Ashkenazi A: Differential hepatocyte toxicity
of recombinant Apo2L/TRAIL versions. Nature Medicine 2001,
7:383-385.
18. Irmler M, Thome M, Hahne M, Schneider P, Hofmann B, Steiner V,
Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE,
Tschopp J: Inhibition of Death Receptor Signals By Cellular
Flip. Nature 1997, 388:190-195.
19. Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki
N, Bonnard M, Goeddel DV, Mak TW: Requirement for casper
(c-FLIP) in regulation of death receptor-induced apoptosis
and embryonic development. Immunity 2000, 12:633-642.
20. Arah IN, Song K, Seth P, Cowan KH, Sinha BK: Role of wild-type
p53 in the enhancement of camptothecin cytotoxicity
against human prostate tumor cells. Anticancer Research 1998,
18:1845-1849.
21. Fulda S, Meyer E, Debatin KM: Metabolic inhibitors sensitize for
CD95 (APO-1/Fas)-induced apoptosis by down-regulating
Fas-associated death domain-like interleukin 1-converting
enzyme inhibitory protein expression. Cancer Research 2000,
60:3947-3956.
22. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer
PH, Peter ME, Wyche JH, Pantazis P: Induction of apoptosis in 9-
nitrocamptothecin-treated DU145 human prostate carci-
noma cells correlates with de novo synthesis of CD95 and
CD95 ligand and down-regulation of c-FLIPshort.  Cancer
Research 2001, 61:7148-7154.
23. Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K:
Cisplatin (CDDP) sensitizes human osteosarcoma cell to
Fas/CD95-mediated apoptosis by down-regulating FLIP-L
expression. International Journal of Cancer 2000, 88:986-991.
24. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar
BR, Zhang X, Elliott PJ, Murphy WJ: The proteasome inhibitor
PS-341 sensitizes neoplastic cells to TRAIL-mediated apop-
tosis by reducing levels of c-FLIP. Blood 2003, 102:303-310.
25. Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H:
Selective inhibition of FLICE-like inhibitory protein (FLIP)
expression with small interfering RNA oligonucleotides (siR-
NAs) is sufficient to sensitize tumor cells for TRAIL-induced
apoptosis. Molecular Medicine 2002, 8:725-732.
26. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Nor-
ris JS: Down-regulation of c-FLIP sensitizes DU145 prostate
cancer cells to Fas-mediated apoptosis. Cancer Biol Ther 2002,
1:401-6.
27. Shankar S, Singh TR, Srivastava RK: Ionizing Radiation Enhances
the Therapeutic Potential of TRAIL in Prostate Cancer in
vitro and in vivo: Intracellular Mechanisms. The Prostate 2004,
61:35-49.
28. Gliniak B, Le T: Tumor necrosis factor-related apoptosis-
inducing ligand's antitumor activity in vivo is enhanced by
the chemotherapeutic agent CPT-11.  Cancer Research 1999,
59:6153-6158.
29. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ:
Increased death receptor 5 expression by chemotherapeutic
agents in human gliomas causes synergistic cytotoxicity with
tumor necrosis factor-related apoptosis-inducing ligand in
vitro and in vivo. Cancer Research 2000, 60:847-853.
30. Liu WH, Bodle E, Chen JY, Gao MX, Rosen GD, Broaddus VC:
Tumor necrosis factor-related apoptosis-inducing ligand and
chemotherapy cooperate to induce apoptosis in mesotheli-
oma cell lines. Am J Respir Cell Mol Biol 2001, 25:111-118.
31. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S: Chem-
otherapy augments TRAIL-induced apoptosis in breast cell
lines. Cancer Research 1999, 59:734-741.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/2/prepub